Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110

Paul J Hengeveld; Y Emre Ertem; Julie M N Dubois; Clemens H M Mellink; Anne-Marie van der Kevie-Kersemaekers; Ludo M Evers; Kim Heezen; P Martijn Kolijn; Olaf R F Mook; M Mahdi Motazacker; Kazem Nasserinejad; S Kersting; Peter E Westerweel; Carsten U Niemann; Arnon P Kater; Anton W Langerak; Mark-David Levin

doi:10.1038/s41375-022-01600-6

Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110

Paul J Hengeveld
, Y Emre Ertem
, Julie M N Dubois
, Clemens H M Mellink
, Anne-Marie van der Kevie-Kersemaekers
, Ludo M Evers
, Kim Heezen
, P Martijn Kolijn
, Olaf R F Mook
, M Mahdi Motazacker
, Kazem Nasserinejad
, S Kersting
, Peter E Westerweel
, Carsten U Niemann
, Arnon P Kater
, Anton W Langerak
, Mark-David Levin

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	1935-1938
Number of pages	4
Journal	Leukemia
Volume	36
Issue number	7
DOIs	https://doi.org/10.1038/s41375-022-01600-6
Publication status	Published - Jul 2022
Externally published	Yes

Keywords

Humans
Immunoglobulin Heavy Chains
Immunoglobulin Variable Region
Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
Treatment Outcome

Access to Document

10.1038/s41375-022-01600-6

Cite this

Hengeveld, P. J., Ertem, Y. E., Dubois, J. M. N., Mellink, C. H. M., van der Kevie-Kersemaekers, A.-M., Evers, L. M., Heezen, K., Kolijn, P. M., Mook, O. R. F., Motazacker, M. M., Nasserinejad, K., Kersting, S., Westerweel, P. E., Niemann, C. U., Kater, A. P., Langerak, A. W., & Levin, M.-D. (2022). Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110. Leukemia, 36(7), 1935-1938. https://doi.org/10.1038/s41375-022-01600-6

@article{c3c13ae026bb473290a8299d9d543643,

title = "Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110",

keywords = "Humans, Immunoglobulin Heavy Chains, Immunoglobulin Variable Region, Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy, Treatment Outcome",

author = "Hengeveld, \{Paul J\} and Ertem, \{Y Emre\} and Dubois, \{Julie M N\} and Mellink, \{Clemens H M\} and \{van der Kevie-Kersemaekers\}, Anne-Marie and Evers, \{Ludo M\} and Kim Heezen and Kolijn, \{P Martijn\} and Mook, \{Olaf R F\} and Motazacker, \{M Mahdi\} and Kazem Nasserinejad and S Kersting and Westerweel, \{Peter E\} and Niemann, \{Carsten U\} and Kater, \{Arnon P\} and Langerak, \{Anton W\} and Mark-David Levin",

year = "2022",

month = jul,

doi = "10.1038/s41375-022-01600-6",

language = "English",

volume = "36",

pages = "1935--1938",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "7",

}

Hengeveld, PJ, Ertem, YE, Dubois, JMN, Mellink, CHM, van der Kevie-Kersemaekers, A-M, Evers, LM, Heezen, K, Kolijn, PM, Mook, ORF, Motazacker, MM, Nasserinejad, K, Kersting, S, Westerweel, PE, Niemann, CU, Kater, AP, Langerak, AW & Levin, M-D 2022, 'Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110', Leukemia, vol. 36, no. 7, pp. 1935-1938. https://doi.org/10.1038/s41375-022-01600-6

TY - JOUR

T1 - Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110

AU - Hengeveld, Paul J

AU - Ertem, Y Emre

AU - Dubois, Julie M N

AU - Mellink, Clemens H M

AU - van der Kevie-Kersemaekers, Anne-Marie

AU - Evers, Ludo M

AU - Heezen, Kim

AU - Kolijn, P Martijn

AU - Mook, Olaf R F

AU - Motazacker, M Mahdi

AU - Nasserinejad, Kazem

AU - Kersting, S

AU - Westerweel, Peter E

AU - Niemann, Carsten U

AU - Kater, Arnon P

AU - Langerak, Anton W

AU - Levin, Mark-David

PY - 2022/7

Y1 - 2022/7

KW - Humans

KW - Immunoglobulin Heavy Chains

KW - Immunoglobulin Variable Region

KW - Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy

KW - Treatment Outcome

UR - https://www.scopus.com/pages/publications/85130283203

U2 - 10.1038/s41375-022-01600-6

DO - 10.1038/s41375-022-01600-6

M3 - Comment/Letter to the editor

C2 - 35585140

SN - 0887-6924

VL - 36

SP - 1935

EP - 1938

JO - Leukemia

JF - Leukemia

IS - 7

ER -

Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110

Keywords

Access to Document

Other files and links

Cite this